Virpax Chairman resigns citing policy disputes; auditor EisnerAmper resigns

Virpax Pharmaceuticals, Inc.

Chairman Eric Floyd resigned Sept 20, 2024, disagreeing with salary cuts and elimination of D&O insurance.
Floyd warned D&O elimination could expose directors/officers to personal liability and hurt retention.
EisnerAmper resigned as auditor Sept 20, 2024; no accounting disagreements were reported.
New auditor Bush & Associated CPA LLC engaged Sept 24, 2024, approved by Audit Committee and Board.
EisnerAmper's prior audit reports included a going-concern explanatory paragraph for FY2022 and FY2023.

item 4.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Eric Floyd

Chairman of the Board

Virpax Pharmaceuticals, Inc.

Effective: 2024-09-20
Filed: September 25, 2024, 7:59 PM ET

On September 20, 2024, Eric Floyd, Chairman of the Board, notified the Company of his intention to resign from the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Eric Floyd resigned as Chairman of the Board at Virpax Pharmaceuticals, Inc..

Action: resigned
Role: Chairman of the Board

Exact text from the filing

On September 20, 2024, Eric Floyd, Chairman of the Board, notified the Company of his intention to resign from the Board, effective immediately.

View on SEC.gov

Source: SEC EDGAR

accession 0001731122-24-001482

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.